Vincerx Pharma Has Dosed The First Patient In Phase 1 Trial Of VIP943 For Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, And B-cell Acute Lymphoblastic Leukemia; Preliminary Safety And Pharmacology Data Is Expected In 2024
Benzinga Newsdesk - Sep 14, 2023, 7:02AM